Bendamustine

Bendamustine2DCSD

Figure 4 (8530146434).png

Bendamustine is a chemotherapy medication used in the treatment of certain types of cancer. It is classified as an alkylating agent and is primarily used to treat chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Bendamustine is known for its unique mechanism of action, which combines properties of both alkylating agents and antimetabolites.

Medical Uses[edit]

Bendamustine is indicated for the treatment of:

Chronic lymphocytic leukemia (CLL)
Non-Hodgkin lymphoma (NHL), particularly in patients who have not responded to other treatments

Mechanism of Action[edit]

Bendamustine works by causing DNA damage in cancer cells, which leads to cell death. It forms cross-links between DNA strands, preventing the cancer cells from dividing and growing. This dual mechanism of action, involving both alkylation and antimetabolite activity, makes bendamustine effective against cancer cells that may be resistant to other treatments.

Administration[edit]

Bendamustine is administered intravenously. The dosage and treatment schedule depend on the type of cancer being treated, the patient's overall health, and other factors. It is typically given in cycles, with periods of treatment followed by periods of rest.

Side Effects[edit]

Common side effects of bendamustine include:

Nausea
Vomiting
Fatigue
Fever
Infections due to lowered white blood cell counts
Anemia
Thrombocytopenia

Serious side effects can include severe infections, allergic reactions, and secondary cancers.

History[edit]

Bendamustine was first synthesized in the 1960s in the former East Germany. It was approved for medical use in the United States by the Food and Drug Administration (FDA) in 2008.

Research[edit]

Ongoing research is exploring the use of bendamustine in combination with other chemotherapy agents and targeted therapies to improve outcomes for patients with various types of cancer.

References[edit]

External Links[edit]

This medical article is a stub. You can help WikiMD by expanding the page.